| Literature DB >> 23555908 |
Jianguo Qiu1, Shuting Chen, Prasoon Pankaj, Hong Wu.
Abstract
BACKGROUND: Laparoscopic hepatectomy (LH) for management of hepatic colorectal metastases (HCRM) is commonly being performed; however, there are limited reports comparing LH outcomes with those of open hepatectomy (OH) procedure. The aim of the present study was to compare perioperative outcomes between the LH and OH procedures performed at a single medical center.Entities:
Mesh:
Year: 2013 PMID: 23555908 PMCID: PMC3605322 DOI: 10.1371/journal.pone.0060153
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow chart of attempted hepatectomy.
Clinicopathologic characteristics of all included patients.
| Clinical characteristics | All (n = 170) | LH (n = 30) | OH (n = 140) | P values (LH vs. OH) |
| Sex(male/female) | 80/90 | 14/16 | 66/74 | 0.96 |
| Age(year) | 53.4±11.7 | 52.5±11.5 | 54.2±12.5 | 0.58 |
| Heights(cm) | 167.6±6.2 | 164.5±6.6 | 168.2±5.7 | 0.20 |
| Body wight(kg/m2) | 23±4.5 | 22.4±5.0 | 24±7.5 | 0.14 |
| ASA status(I/II/III) | 110/48/12 | 15/13/2 | 90/35/15 | 0.15 |
| Child A/B/C | 132/33/5 | 25/4/1 | 110/25/5 | 0.56 |
| Liver cirrhosis(n) | 17 | 2 | 15 | 0.23 |
| Primary tumor location | 0.56 | |||
| Rectum | 67 | 11 | 61 | |
| Colon | 89 | 19 | 79 | |
| Serum CEA (U/ml) | 220±56.8 | 200±40 | 220±50 | 0.25 |
| Tumor location(segments) | 0.75 | |||
| I | 3 | 0 | 5 | |
| II–III | 94 | 13 | 72 | |
| IV | 20 | 6 | 18 | |
| V–VI | 45 | 10 | 37 | |
| VII–VIII | 4 | 1 | 8 | |
| Timor size(cm) | 3.4±1.8 | 2.5±2.0 | 3.7±2.5 | 0.004 |
| Metastatic tumor number(1/≥2) | 100/70 | 20/10 | 80/60 | <0.001 |
| Tumor presentation | 0.55 | |||
| Synchronous | 49 | 10 | 39 | |
| Metachonous | 121 | 20 | 101 | |
| Preoperative chemotherapy | 95 | 13 | 85 | 0.08 |
| Postoperative chemotherapy | 130 | 17 | 110 | 0.01 |
| Operative time(minutes) | 340±80 | 235±70 | 365±90 | <0.001 |
| Blood loss(ml) | 358±250 | 215±170 | 390±240 | <0.001 |
| Dose of analgesic (mg) | 50.2±35.4 | 30.2±20.8 | 76.1±44.6 | <0.001 |
| Times analgesic given | 3.3±0.6 | 2.0±0.5 | 5.0±0.8 | 0.02 |
| Margins(1–10mm/>1cm) | 16/154 | 2/28 | 14/126 | 0.57 |
| Specimen weight(g) | 310±95 | 245±45 | 345±110 | <0.001 |
| Surgical margins(mm) | 10±6 | 9±5 | 12±7 | 0.006 |
| Hospital stay(d) | 10.4±2.3 | 7.5±1.5 | 11.5±3.0 | <0.001 |
| Overall complication rate | 39.4% | 26.2% | 55% | <0.001 |
CEA:Cancer Embryo Antigen.
Characteristics comparison of the 30 patients who underwent LH with matched 30 patients who underwent OH procedure.
| Clinical characteristics | LH (n = 30) | OH (n = 30) | P values |
| Sex(male/female) | 14/16 | 15/15 | 0.61 |
| ASA status(I/II/III) | 15/13/2 | 16/11/3 | 0.80 |
| Child A/B/C | 15/13/2 | 15/12/3 | 0.64 |
| Liver cirrhosis | 2 | 3 | 0.64 |
| Primary tumor type | 0.79 | ||
| Rectum carcinoma | 10 | 11 | |
| Colon carcinoma | 20 | 19 | |
| Serum CEA (U/ml) | 200±40 | 224±55 | 0.30 |
| Tumor location(segments) | 0.80 | ||
| II–III | 13 | 14 | |
| IV | 6 | 6 | |
| V–VI | 10 | 8 | |
| VII–VIII | 1 | 2 | |
| Largest tumor size(cm) | 2.5±2.0 | 2.8±1.5 | 0.51 |
| Metastatic tumor number(1/≥2) | 20/10 | 21/9 | 0.78 |
| Tumor presentation | 0.79 | ||
| Synchronous | 10 | 11 | |
| Metachonous | 20 | 19 | |
| Preoperative chemotherapy | 13 | 15 | 0.61 |
| Postoperative chemotherapy | 17 | 18 | 0.79 |
ASA: American Society of Anesthesiology.
Operative findings and postoperative laboratory test for matched cohort.
| Parameters | LH(n = 30) | OH(n = 30) | P values |
| Left hemihepatectomy | 1 | 2 | 0.56 |
| Right hemihepatectomy | 1 | 3 | 0.32 |
| Bisegementectomy | 12 | 12 | 1.00 |
| Segementectomy | 9 | 7 | 0.58 |
| Subsegementectomy | 7 | 6 | 0.75 |
| Operative time(minutes) | 235±70 | 255±80 | 0.30 |
| Blood loss(ml) | 215±170 | 385±260 | <0.001 |
| Hospital stay(d) | 7.5±1.5 | 11.5±3.0 | <0.001 |
| Dose of analgesic (mg) | 30.2±20.8 | 70.3±38.5 | <0.0001 |
| Times analgesic given | 2.0±0.5 | 4.0±0.8 | <0.0001 |
| Time bowel function returned (d) | 1.0±0.9 | 2.4±1.8 | <0.0001 |
| Time to first defecation (d) | 2.2±0.7 | 4.0±1.5 | <0.0001 |
| Tiem to toleration of soft diet (d) | 1.8±1.2 | 3.2±1.0 | <0.001 |
| Specimen weight(g) | 245±45 | 255±50 | 0.55 |
| Surgical margins(mm) | 9±5 | 10±5 | 0.44 |
| Blood test parameters | |||
| ALT(mmol/L, post 1 to 3 d) | 250±175 | 285±180 | 0.42 |
| AST(mmol/L, post 1 to 3 d) | 262±140 | 291±150 | 0.65 |
| TBIL(mmol/L, post 1 to 3 d) | 25.2±15 | 27±19.5 | 0.56 |
ALT: Alanine aminotransferase; AST: aspartate aminotransferase; TBIL: Total bilirubin; post: postoperative.
Clinicopathologic of patients who underwent laparoscopic liver resections for colorectal liver metastases searched from Pubmed database.
| Study&year | Enrolled Patients | Tumor Diameter(cm) | Morbidity | Mortality | Surgical margins(cm) | Overall survival (%) | Disease-free survival (%) |
| Gigot | 10 | ND | ND | 0 | ND | ND | ND |
| Mala | 15 | 2.6(1–6) | 13.3% | 0 | 71%≥1cm | ND | ND |
| O”Rourke | 22 | ND | ND | 0 | 54%≥1cm | 2-year: 75% | 2-year: 67% |
| Dulucp | 11 | ND | ND | ND | 100%≥1cm | ND | ND |
| Mala | 42 | 3 (0.8–15) | 94% R0 | 0 | ND | ND | ND |
| Vibert | 41 | 3 (1–17) | ND | ND | Median:0.5cm | 3-year: 87% | 3-year: 51% |
| Alkari | 20 | ND | 4% | 0 | R0: 84.2% | 89% | 79% |
| Spencer | 13 | ND | ND | 0 | 1 (1–4.5) | ND | ND |
| Sasaki | 39 | 3.5±3.0 | 5.7% | 0 | 0.5 (0 – 4) | 5 years 64% | ND |
| Robles | 21 | 4 | ND | 0 | R0: 100% | 3-year: 80% | ND |
| Buell | 31 | 3.6 | ND | ND | R0: 100% | ND | ND |
| Bryant | 22 | 3 (0.8–7) | ND | ND | 2±1.7 mm | 5-year: 64% | 5-year: 47% |
| Patriti | 7 | ND | 0 | 0 | R0: 100% | ND | ND |
| Nguyen | 109 | 3 (4–15.2) | 11.9% | 0 | 94.4%≥1cm | 5-year: 50% | 5-year: 43% |
| Sanchez | 6 | 5 (2–11) | ND | ND | ND | ND | ND |
| Kazaryan | 107 | 5 (2–11) | 11.9% | ND | 0.3 (0.5–1.2) | 5-year: 51% | 5-year: 42% |
| Airazat | 96 | ND | ND | ND | ND | ND | ND |
| Hilal | 55 | ND | 15% | 0 | 1.7 (0.1– 6.0) | 90% | ND |
| Lee | 10 | 3.9±2.0 | 10% | 0 | R0: 100% | ND | ND |
| Tranchart | 2 | ND | 0 | 0 | R0: 100% | ND | ND |
| Huh | 20 | 2.0 (0.9–5.5) | 50% | 0 | R0: 100% | 3-year: 58.7% | 3-year: 52.8% |
| Abu Hilal | 80 | 2.5 (0.5–10.5) | 11% | ND | R0: 96% | 78% | ND |
| Topal | 20 | 4(4–7) | 35% | 0 | R0: 95% | 5-year: 48% | 5-year: 43% |
: after follow-up of 22 months.
: after median follow-up of 22 months.
: after a median (range) follow-up period of 13.5 (5–36) months.
ND: not dimensioned.